{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:35:56Z","timestamp":1790436956235,"version":"4.1.0"},"reference-count":137,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ecl.2022.02.006","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T07:36:52Z","timestamp":1656920212000},"page":"511-537","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["The Inherited Hypercholesterolemias"],"prefix":"10.1016","volume":"51","author":[{"given":"Wann Jia","family":"Loh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ecl.2022.02.006_bib1","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1194\/jlr.P900033-JLR200","article-title":"Genetic and environmental influences on factors associated with cardiovascular disease and the metabolic syndrome","volume":"50","author":"Elder","year":"2009","journal-title":"J\u00a0Lipid Res"},{"issue":"45","key":"10.1016\/j.ecl.2022.02.006_bib2","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ecl.2022.02.006_bib3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijcard.2015.03.027","article-title":"Prevalence and treatment of familial hypercholesterolaemia in Australian communities","volume":"185","author":"Watts","year":"2015","journal-title":"Int J Cardiol"},{"issue":"9","key":"10.1016\/j.ecl.2022.02.006_bib4","doi-asserted-by":"crossref","first-page":"e016461","DOI":"10.1136\/bmjopen-2017-016461","article-title":"Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis","volume":"7","author":"Akioyamen","year":"2017","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.ecl.2022.02.006_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41569-018-0052-6","article-title":"The complex molecular genetics of familial hypercholesterolaemia","volume":"16","author":"Berberich","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10.1016\/j.ecl.2022.02.006_bib6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.atherosclerosis.2015.04.809","article-title":"Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European Society of Cardiology","volume":"241","author":"De Backer","year":"2015","journal-title":"Atherosclerosis"},{"issue":"8","key":"10.1016\/j.ecl.2022.02.006_bib7","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nrendo.2016.69","article-title":"Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism","volume":"12","author":"Ellis","year":"2016","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"10.1016\/j.ecl.2022.02.006_bib8","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41569-019-0325-8","article-title":"Familial hypercholesterolaemia: evolving knowledge for designing adaptive models of care","volume":"17","author":"Watts","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"10.1016\/j.ecl.2022.02.006_bib9","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1469-1809.2012.00724.x","article-title":"Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment","volume":"76","author":"Usifo","year":"2012","journal-title":"Ann Hum Genet"},{"issue":"1","key":"10.1016\/j.ecl.2022.02.006_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.gene.2014.09.020","article-title":"The history of Autosomal Recessive Hypercholesterolemia (ARH). From clinical observations to gene identification","volume":"555","author":"Fellin","year":"2015","journal-title":"Gene"},{"issue":"6807","key":"10.1016\/j.ecl.2022.02.006_bib11","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/bmj.303.6807.893","article-title":"Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group","volume":"303","year":"1991","journal-title":"BMJ"},{"issue":"22","key":"10.1016\/j.ecl.2022.02.006_bib12","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The Agenda for Familial Hypercholesterolemia: a Scientific Statement From the American Heart Association","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ecl.2022.02.006_bib13","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ijcard.2014.04.165","article-title":"Familial hypercholesterolemia in China: prevalence and evidence of underdetection and undertreatment in a community population","volume":"174","author":"Shi","year":"2014","journal-title":"Int J Cardiol"},{"issue":"8","key":"10.1016\/j.ecl.2022.02.006_bib14","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5551\/jat.CR003","article-title":"Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017","volume":"25","author":"Harada-Shiba","year":"2018","journal-title":"J\u00a0Atheroscler Thromb"},{"issue":"3","key":"10.1016\/j.ecl.2022.02.006_bib15","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.hlc.2020.09.943","article-title":"Integrated guidance for enhancing the care of familial hypercholesterolaemia in Australia","volume":"30","author":"Watts","year":"2021","journal-title":"Heart Lung Circ"},{"issue":"12","key":"10.1016\/j.ecl.2022.02.006_bib16","first-page":"1553","article-title":"Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018","volume":"34","author":"Brunham","year":"2018","journal-title":"Can J Cardiol"},{"issue":"22","key":"10.1016\/j.ecl.2022.02.006_bib17","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia","volume":"67","author":"Khera","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.ecl.2022.02.006_bib18","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2016.01.008","article-title":"Attainment of LDL-Cholesterol treatment goals in patients with familial hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up","volume":"67","author":"Perez de Isla","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.ecl.2022.02.006_bib19","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jacc.2018.05.044","article-title":"Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel","volume":"72","author":"Sturm","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ecl.2022.02.006_bib20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.atherosclerosis.2019.02.003","article-title":"Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia","volume":"284","author":"Perez-Calahorra","year":"2019","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.ecl.2022.02.006_bib21","doi-asserted-by":"crossref","first-page":"e006553","DOI":"10.1161\/JAHA.117.006553","article-title":"Putting into perspective the hazards of untreated familial hypercholesterolemia","volume":"6","author":"Hopkins","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.ecl.2022.02.006_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2016.07.007","article-title":"Prevalence of potential familial hypercholesteremia (FH) in 54,811 statin-treated patients in clinical practice","volume":"252","author":"Catapano","year":"2016","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.ecl.2022.02.006_bib23","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/jamacardio.2019.3903","article-title":"Association of low-density lipoprotein cholesterol with risk of aortic valve stenosis in familial hypercholesterolemia","volume":"4","author":"Mundal","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.ecl.2022.02.006_bib24","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1161\/STROKEAHA.118.023456","article-title":"Risk of ischemic stroke and total cerebrovascular disease in familial hypercholesterolemia","volume":"50","author":"Hovland","year":"2019","journal-title":"Stroke"},{"issue":"12","key":"10.1016\/j.ecl.2022.02.006_bib25","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1210\/jc.2018-01058","article-title":"Familial hypercholesterolemia and risk of peripheral arterial disease and chronic kidney disease","volume":"103","author":"Emanuelsson","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.ecl.2022.02.006_bib26","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S2213-8587(16)30041-9","article-title":"Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel","volume":"4","author":"Santos","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"22","key":"10.1016\/j.ecl.2022.02.006_bib27","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1161\/CIRCULATIONAHA.116.024541","article-title":"Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART Registry (Spanish Familial Hypercholesterolemia Cohort Study)","volume":"135","author":"Perez de Isla","year":"2017","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.ecl.2022.02.006_bib28","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1161\/ATVBAHA.121.316106","article-title":"Familial hypercholesterolemia-risk-score: a new score predicting cardiovascular events and cardiovascular mortality in familial hypercholesterolemia","volume":"41","author":"Paquette","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"10.1016\/j.ecl.2022.02.006_bib29","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.jcmg.2021.06.011","article-title":"The added value of coronary calcium score in predicting cardiovascular events in familial hypercholesterolemia","volume":"14","author":"Gallo","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.ecl.2022.02.006_bib30","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ecl.2022.02.006_bib31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2021.03.039","article-title":"Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force","volume":"325","author":"Averna","year":"2021","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.ecl.2022.02.006_bib32","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.ecl.2022.02.006_bib33","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran for the treatment of heterozygous familial hypercholesterolemia","volume":"382","author":"Raal","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ecl.2022.02.006_bib34","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13023-021-01749-w","article-title":"Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients","volume":"16","author":"Visek","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"9860","key":"10.1016\/j.ecl.2022.02.006_bib35","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ecl.2022.02.006_bib36","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for Homozygous Familial Hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"7859","key":"10.1016\/j.ecl.2022.02.006_bib37","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","article-title":"In\u00a0vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.ecl.2022.02.006_bib38","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1161\/CIRCRESAHA.118.311227","article-title":"PCSK9: from basic science discoveries to clinical trials","volume":"122","author":"Shapiro","year":"2018","journal-title":"Circ Res"},{"issue":"6","key":"10.1016\/j.ecl.2022.02.006_bib39","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jacbts.2019.05.008","article-title":"Angiopoietin-Like 3: from discovery to therapeutic gene editing","volume":"4","author":"Wang","year":"2019","journal-title":"JACC Basic Transl Sci"},{"issue":"6","key":"10.1016\/j.ecl.2022.02.006_bib40","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/MOL.0000000000000790","article-title":"Management of familial hypercholesterolemia in pregnancy","volume":"32","author":"Graham","year":"2021","journal-title":"Curr Opin Lipidol"},{"issue":"4","key":"10.1016\/j.ecl.2022.02.006_bib41","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-2125.2007.02905.x","article-title":"Risk of congenital anomalies in pregnant users of statin drugs","volume":"64","author":"Ofori","year":"2007","journal-title":"Br J Clin Pharmacol"},{"issue":"16","key":"10.1016\/j.ecl.2022.02.006_bib42","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-year follow-up of statins in children with familial hypercholesterolemia","volume":"381","author":"Luirink","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"36","key":"10.1016\/j.ecl.2022.02.006_bib43","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","article-title":"Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment","volume":"36","author":"Wiegman","year":"2015","journal-title":"Eur Heart J"},{"issue":"13","key":"10.1016\/j.ecl.2022.02.006_bib44","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/CIRCULATIONAHA.118.035658","article-title":"Whole-Genome Sequencing to Characterize Monogenic and Polygenic Contributions in Patients Hospitalized With Early-Onset Myocardial Infarction","volume":"139","author":"Khera","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ecl.2022.02.006_bib45","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41525-021-00190-z","article-title":"Genetic basis of hypercholesterolemia in adults","volume":"6","author":"Saadatagah","year":"2021","journal-title":"NPJ Genom Med"},{"issue":"2","key":"10.1016\/j.ecl.2022.02.006_bib46","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/MOL.0000000000000737","article-title":"Polygenic scores for dyslipidemia: the emerging genomic model of plasma lipoprotein trait inheritance","volume":"32","author":"Trinder","year":"2021","journal-title":"Curr Opin Lipidol"},{"issue":"6","key":"10.1016\/j.ecl.2022.02.006_bib47","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrendo.2012.15","article-title":"The genetics of familial combined hyperlipidaemia","volume":"8","author":"Brouwers","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ecl.2022.02.006_bib48","doi-asserted-by":"crossref","unstructured":"Brahm, Amanda J, and Robert A Hegele. Combined hyperlipidemia: familial but not (usually) monogenic.Current opinion in lipidology\u00a0vol. 27,2 (2016): 131-40.","DOI":"10.1097\/MOL.0000000000000270"},{"issue":"11","key":"10.1016\/j.ecl.2022.02.006_bib49","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1161\/01.ATV.14.11.1687","article-title":"Genetic predictors of FCHL in four large pedigrees. Influence of ApoB level major locus predicted genotype and LDL subclass phenotype","volume":"14","author":"Jarvik","year":"1994","journal-title":"Arterioscler Thromb"},{"issue":"7","key":"10.1016\/j.ecl.2022.02.006_bib50","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1161\/01.ATV.13.7.1110","article-title":"Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia","volume":"13","author":"Venkatesan","year":"1993","journal-title":"Arterioscler Thromb"},{"issue":"10","key":"10.1016\/j.ecl.2022.02.006_bib51","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1161\/01.ATV.12.10.1176","article-title":"Familial combined hyperlipidemia and abnormal lipoprotein lipase","volume":"12","author":"Babirak","year":"1992","journal-title":"Arterioscler Thromb"},{"issue":"6","key":"10.1016\/j.ecl.2022.02.006_bib52","first-page":"877","article-title":"Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date","volume":"3","author":"Gaddi","year":"2007","journal-title":"Vasc Health Risk Manag"},{"issue":"24","key":"10.1016\/j.ecl.2022.02.006_bib53","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1161\/01.CIR.0000130646.93255.86","article-title":"Nomogram to diagnose familial combined hyperlipidemia on the basis of results of a 5-year follow-up study","volume":"109","author":"Veerkamp","year":"2004","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ecl.2022.02.006_bib54","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1161\/hq0202.104059","article-title":"Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study","volume":"22","author":"Veerkamp","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"10.1016\/j.ecl.2022.02.006_bib55","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.aprim.2014.04.013","article-title":"[Familial combined hyperlipidemia: consensus document]","volume":"46","author":"Mata","year":"2014","journal-title":"Aten Primaria"},{"issue":"8","key":"10.1016\/j.ecl.2022.02.006_bib56","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0002-9149(93)91002-Y","article-title":"Prevalence of hyperapobetalipoproteinemia and other lipoprotein phenotypes in men (aged < or\u00a0= 50 years) and women (< or\u00a0= 60 years) with coronary artery disease","volume":"71","author":"Kwiterovich","year":"1993","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.ecl.2022.02.006_bib57","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1161\/01.CIR.0000081777.17879.85","article-title":"Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung, and Blood Institute Family Heart Study","volume":"108","author":"Hopkins","year":"2003","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ecl.2022.02.006_bib58","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-001107","article-title":"Incidence of type 2 diabetes in familial combined hyperlipidemia","volume":"8","author":"Brouwers","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"11","key":"10.1016\/j.ecl.2022.02.006_bib59","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/S0022-2275(20)32417-2","article-title":"Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes","volume":"40","author":"Mahley","year":"1999","journal-title":"J\u00a0Lipid Res"},{"issue":"24","key":"10.1016\/j.ecl.2022.02.006_bib60","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1161\/01.CIR.101.24.2777","article-title":"Cardiovascular disease mortality in familial forms of hypertriglyceridemia: a 20-year prospective study","volume":"101","author":"Austin","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ecl.2022.02.006_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2018.11.013","article-title":"Incidence of cardiovascular disease in familial combined hyperlipidemia: a 15-year follow-up study","volume":"280","author":"Luijten","year":"2019","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.ecl.2022.02.006_bib62","first-page":"2545","article-title":"USF-1 genetic polymorphisms confer a high risk of nonalcoholic fatty liver disease in Chinese population","volume":"8","author":"Wang","year":"2015","journal-title":"Int J Clin Exp Med"},{"issue":"9","key":"10.1016\/j.ecl.2022.02.006_bib63","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee","volume":"78","author":"Virani","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.ecl.2022.02.006_bib64","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.ecl.2022.02.006_bib65","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.metabol.2007.06.021","article-title":"Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia","volume":"56","author":"Arca","year":"2007","journal-title":"Metabolism"},{"key":"10.1016\/j.ecl.2022.02.006_bib66","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.2741\/4635","article-title":"Lipoprotein(a) and cardiovascular disease: current state and future directions for an enigmatic lipoprotein","volume":"23","author":"Saeed","year":"2018","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"26","key":"10.1016\/j.ecl.2022.02.006_bib67","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ecl.2022.02.006_bib68","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.ecl.2022.02.006_bib69","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Emerging Risk Factors","year":"2009","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ecl.2022.02.006_bib70","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.ecl.2022.02.006_bib71","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated Lipoprotein(a) and Risk of Ischemic Stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.ecl.2022.02.006_bib72","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ecl.2022.02.006_bib73","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large National Biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ecl.2022.02.006_bib74","article-title":"Lipoprotein(a) as predictor of coronary artery disease and myocardial infarction in a multi-ethnic Asian population","author":"Loh","year":"2021","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.ecl.2022.02.006_bib75","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","article-title":"Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease","volume":"16","author":"Boffa","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"23","key":"10.1016\/j.ecl.2022.02.006_bib76","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.ecl.2022.02.006_bib77","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jacc.2018.12.037","article-title":"Value of measuring lipoprotein(a) during cascade testing for familial hypercholesterolemia","volume":"73","author":"Ellis","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.ecl.2022.02.006_bib78","doi-asserted-by":"crossref","first-page":"e011781","DOI":"10.1161\/JAHA.118.011781","article-title":"Lipoprotein(a) particle production as a determinant of plasma lipoprotein(a) concentration across varying apolipoprotein(a) isoform sizes and background cholesterol-lowering therapy","volume":"8","author":"Chan","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.ecl.2022.02.006_bib79","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s10157-013-0875-8","article-title":"Causes and consequences of lipoprotein(a) abnormalities in kidney disease","volume":"18","author":"Kronenberg","year":"2014","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"10.1016\/j.ecl.2022.02.006_bib80","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jacl.2012.01.007","article-title":"Significant reduction of elevated serum lipoprotein(a) concentrations during levo-thyroxine-replacement therapy in a hypothyroid patient","volume":"6","author":"Murase","year":"2012","journal-title":"J\u00a0Clin Lipidol"},{"issue":"42","key":"10.1016\/j.ecl.2022.02.006_bib81","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1093\/eurheartj\/eht053","article-title":"When should we measure lipoprotein (a)?","volume":"34","author":"Kostner","year":"2013","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.ecl.2022.02.006_bib82","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1172\/JCI45277","article-title":"Farnesoid X receptor represses hepatic human APOA gene expression","volume":"121","author":"Chennamsetty","year":"2011","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.ecl.2022.02.006_bib83","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of Alirocumab on Lipoprotein(a) and cardiovascular risk after acute coronary syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ecl.2022.02.006_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.03.003","article-title":"The dedicated \"Lp(a) clinic\": A concept whose time has arrived?","volume":"300","author":"Tsimikas","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ecl.2022.02.006_bib85","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.atherosclerosis.2019.07.001","article-title":"Statin treatment increases lipoprotein(a) levels in subjects with low molecular weight apolipoprotein(a) phenotype","volume":"289","author":"Yahya","year":"2019","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.ecl.2022.02.006_bib86","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1172\/JCI113093","article-title":"Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma","volume":"80","author":"Utermann","year":"1987","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"10.1016\/j.ecl.2022.02.006_bib87","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1172\/JCI115248","article-title":"Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis","volume":"87","author":"Lackner","year":"1991","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.ecl.2022.02.006_bib88","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/ATVBAHA.120.314965","article-title":"Genome-Wide Association Study Highlights APOH as a Novel Locus for Lipoprotein(a) Levels-Brief Report","volume":"41","author":"Hoekstra","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.ecl.2022.02.006_bib89","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1161\/ATVBAHA.120.315300","article-title":"Genome-Wide Association Study and Identification of a Protective Missense Variant on Lipoprotein(a) concentration: protective missense variant on lipoprotein(a) concentration-brief report","volume":"41","author":"Said","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"10.1016\/j.ecl.2022.02.006_bib90","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA Variants With risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10.1016\/j.ecl.2022.02.006_bib91","first-page":"1","article-title":"Clinical Utility of Lipoprotein(a) and LPA genetic risk score in risk prediction of incident atherosclerotic cardiovascular disease","volume":"6","author":"Trinder","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.ecl.2022.02.006_bib92","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/ng.2480","article-title":"Large-scale association analysis identifies new risk loci for coronary artery disease","volume":"45","author":"Consortium","year":"2013","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.ecl.2022.02.006_bib93","first-page":"e48","article-title":"Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"10.1016\/j.ecl.2022.02.006_bib94","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups","volume":"139","author":"Pare","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ecl.2022.02.006_bib95","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/CIRCULATIONAHA.116.024611","article-title":"LPA gene, ethnicity, and cardiovascular events","volume":"135","author":"Lee","year":"2017","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.ecl.2022.02.006_bib96","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1194\/jlr.P091009","article-title":"A\u00a0genome-wide association study on lipoprotein (a) levels and coronary artery disease severity in a Chinese population","volume":"60","author":"Liu","year":"2019","journal-title":"J\u00a0Lipid Res"},{"issue":"2","key":"10.1016\/j.ecl.2022.02.006_bib97","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.atherosclerosis.2015.07.015","article-title":"Lack of association of rs3798220 with small apolipoprotein(a) isoforms and high lipoprotein(a) levels in East and Southeast Asians","volume":"242","author":"Khalifa","year":"2015","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.ecl.2022.02.006_bib98","doi-asserted-by":"crossref","first-page":"9060","DOI":"10.1016\/S0021-9258(17)37076-X","article-title":"Molecular basis for \"null\" lipoprotein(a) phenotypes and the influence of apolipoprotein(a) size on plasma lipoprotein(a) level in the baboon","volume":"269","author":"White","year":"1994","journal-title":"J\u00a0Biol Chem"},{"issue":"2","key":"10.1016\/j.ecl.2022.02.006_bib99","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ecl.2022.02.006_bib100","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2019.08.015","article-title":"Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays","volume":"289","author":"Scharnagl","year":"2019","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.ecl.2022.02.006_bib101","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J\u00a0Lipid Res"},{"issue":"6","key":"10.1016\/j.ecl.2022.02.006_bib102","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jacl.2014.08.003","article-title":"Lipoprotein(a) mass: a massively misunderstood metric","volume":"8","author":"McConnell","year":"2014","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.ecl.2022.02.006_bib103","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2019.10.011","article-title":"HEART UK consensus statement on Lipoprotein(a): a call to action","volume":"291","author":"Cegla","year":"2019","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.ecl.2022.02.006_bib104","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association","volume":"13","author":"Wilson","year":"2019","journal-title":"J\u00a0Clin Lipidol"},{"issue":"3","key":"10.1016\/j.ecl.2022.02.006_bib105","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jacl.2018.02.014","article-title":"Relationship between \"LDL-C\", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide","volume":"12","author":"Viney","year":"2018","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.ecl.2022.02.006_bib106","doi-asserted-by":"crossref","first-page":"100053","DOI":"10.1016\/j.jlr.2021.100053","article-title":"Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements","volume":"62","author":"Yeang","year":"2021","journal-title":"J\u00a0Lipid Res"},{"issue":"24","key":"10.1016\/j.ecl.2022.02.006_bib107","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.ecl.2022.02.006_bib108","first-page":"1129","article-title":"2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"issue":"2","key":"10.1016\/j.ecl.2022.02.006_bib109","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/MED.0000000000000624","article-title":"Expert position statements: comparison of recommendations for the care of adults and youth with elevated lipoprotein(a)","volume":"28","author":"Wilson","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.ecl.2022.02.006_bib110","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jpeds.2020.08.042","article-title":"Should Lipoprotein(a) be Measured in Youth?","volume":"228","author":"Kohn","year":"2021","journal-title":"J\u00a0Pediatr"},{"issue":"11","key":"10.1016\/j.ecl.2022.02.006_bib111","first-page":"1263","article-title":"2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult","volume":"32","author":"Anderson","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.ecl.2022.02.006_bib112","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.atherosclerosis.2016.11.010","article-title":"Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study","volume":"256","author":"Perrot","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ecl.2022.02.006_bib113","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.atherosclerosis.2019.06.896","article-title":"Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: pooled analysis of alirocumab phase 3 trials","volume":"288","author":"Ray","year":"2019","journal-title":"Atherosclerosis"},{"issue":"19","key":"10.1016\/j.ecl.2022.02.006_bib114","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1161\/CIRCULATIONAHA.113.004678","article-title":"Effect of the proprotein convertase subtilisin\/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia","volume":"128","author":"Stein","year":"2013","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.ecl.2022.02.006_bib115","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.metabol.2016.08.007","article-title":"Effect of extended-release niacin on plasma lipoprotein(a) levels: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"65","author":"Sahebkar","year":"2016","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.ecl.2022.02.006_bib116","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.pathol.2018.10.016","article-title":"Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a)","volume":"51","author":"Waldmann","year":"2019","journal-title":"Pathology"},{"issue":"3","key":"10.1016\/j.ecl.2022.02.006_bib117","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/ATVBAHA.114.304549","article-title":"Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials","volume":"35","author":"Santos","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"25","key":"10.1016\/j.ecl.2022.02.006_bib118","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ecl.2022.02.006_bib119","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ecl.2022.02.006_bib120","first-page":"142","article-title":"Abstract 13951: Safety, Tolerability and Efficacy of Single-dose Amg 890, a Novel Sirna Targeting Lp(a), in Healthy Subjects and Subjects With Elevated Lp(a)","author":"Koren","year":"2020","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ecl.2022.02.006_bib121","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1172\/JCI107640","article-title":"Beta-sitosterolemia and xanthomatosis. A newly described lipid storage disease in two sisters","volume":"53","author":"Bhattacharyya","year":"1974","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"10.1016\/j.ecl.2022.02.006_bib122","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/humu.1206","article-title":"Mutations in ATP-cassette binding proteins G5 (ABCG5) and G8 (ABCG8) causing sitosterolemia","volume":"18","author":"Hubacek","year":"2001","journal-title":"Hum Mutat"},{"issue":"5497","key":"10.1016\/j.ecl.2022.02.006_bib123","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1126\/science.290.5497.1771","article-title":"Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters","volume":"290","author":"Berge","year":"2000","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.ecl.2022.02.006_bib124","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/jth.13777","article-title":"Two novel variants of the ABCG5 gene cause xanthelasmas and macrothrombocytopenia: a brief review of hematologic abnormalities of sitosterolemia","volume":"15","author":"Bastida","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"issue":"9","key":"10.1016\/j.ecl.2022.02.006_bib125","doi-asserted-by":"crossref","first-page":"783","DOI":"10.5551\/jat.RV17024","article-title":"Sitosterolemia, hypercholesterolemia, and coronary artery disease","volume":"25","author":"Tada","year":"2018","journal-title":"J\u00a0Atheroscler Thromb"},{"issue":"1","key":"10.1016\/j.ecl.2022.02.006_bib126","doi-asserted-by":"crossref","first-page":"7","DOI":"10.6065\/apem.2016.21.1.7","article-title":"Sitosterolemia: a review and update of pathophysiology, clinical spectrum, diagnosis, and management","volume":"21","author":"Yoo","year":"2016","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2022.02.006_bib127","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/CIRCGEN.119.002871","article-title":"Heterozygous ABCG5 Gene deficiency and risk of coronary artery disease","volume":"13","author":"Nomura","year":"2020","journal-title":"Circ Genom Precis Med"},{"issue":"5","key":"10.1016\/j.ecl.2022.02.006_bib128","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1210\/jc.2013-3274","article-title":"Sitosterolemia presenting with severe hypercholesterolemia and intertriginous xanthomas in a breastfed infant: case report and brief review","volume":"99","author":"Park","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.ecl.2022.02.006_bib129","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1111\/j.1742-1241.2008.01841.x","article-title":"Long-term efficacy and safety of ezetimibe 10\u00a0mg in patients with homozygous sitosterolemia: a 2-year, open-label extension study","volume":"62","author":"Lutjohann","year":"2008","journal-title":"Int J Clin Pract"},{"issue":"6","key":"10.1016\/j.ecl.2022.02.006_bib130","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1542\/peds.86.6.977","article-title":"Response to diet and cholestyramine in a patient with sitosterolemia","volume":"86","author":"Belamarich","year":"1990","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.ecl.2022.02.006_bib131","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s10545-017-0093-8","article-title":"Epidemiology, diagnosis, and treatment of cerebrotendinous xanthomatosis (CTX)","volume":"40","author":"Salen","year":"2017","journal-title":"J\u00a0Inherit Metab Dis"},{"issue":"4","key":"10.1016\/j.ecl.2022.02.006_bib132","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/archneur.57.4.520","article-title":"Presence of diarrhea and absence of tendon xanthomas in patients with cerebrotendinous xanthomatosis","volume":"57","author":"Verrips","year":"2000","journal-title":"Arch Neurol"},{"issue":"5","key":"10.1016\/j.ecl.2022.02.006_bib133","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jacl.2018.06.008","article-title":"Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis","volume":"12","author":"Duell","year":"2018","journal-title":"J\u00a0Clin Lipidol"},{"issue":"9","key":"10.1016\/j.ecl.2022.02.006_bib134","doi-asserted-by":"crossref","first-page":"905","DOI":"10.5551\/jat.RV17055","article-title":"Cerebrotendinous xanthomatosis: molecular pathogenesis, clinical spectrum, diagnosis, and disease-modifying treatments","volume":"28","author":"Koyama","year":"2021","journal-title":"J\u00a0Atheroscler Thromb"},{"issue":"10","key":"10.1016\/j.ecl.2022.02.006_bib135","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.4158\/CS-2020-0490","article-title":"Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary","volume":"26","author":"Handelsman","year":"2020","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.ecl.2022.02.006_bib136","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jacl.2017.04.114","article-title":"Toward an international consensus-Integrating lipoprotein apheresis and new lipid-lowering drugs","volume":"11","author":"Stefanutti","year":"2017","journal-title":"J\u00a0Clin Lipidol"},{"issue":"11 Special","key":"10.1016\/j.ecl.2022.02.006_bib137","first-page":"8","article-title":"Lipid Association of India Expert Consensus Statement on Management of Dyslipidemia in Indians 2020: Part III","volume":"68","author":"Puri","year":"2020","journal-title":"J\u00a0Assoc Physicians India"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852922000214?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852922000214?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:46:57Z","timestamp":1760176017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852922000214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":137,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S0889852922000214"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2022.02.006","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Inherited Hypercholesterolemias","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2022.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}